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Hypophosphatemia is a common complication of kidney
transplantation. Tertiary hyperparathyroidism has long been
thought to be the etiology, but hypophosphatemia can occur
despite low parathyroid hormone (PTH) levels and can persist
after high PTH levels normalize. Furthermore, even in the
setting of normal allograft function, hypophosphatemia, and
hyperparathyroidism, calcitriol levels remain inappropriately
low following transplantation, suggesting that mechanisms
other than PTH contribute. Fibroblast growth factor-23
(FGF-23) induces phosphaturia, inhibits calcitriol synthesis,
and accumulates in chronic kidney disease. We performed a
prospective, longitudinal study of 27 living donor transplant
recipients to test the hypotheses that excessive FGF-23
accounts for hypophosphatemia and decreased calcitriol
levels following kidney transplantation. Hypophosphatemia
o2.5 mg/dl developed in 85% of subjects, including one who
had previously undergone parathyroidectomy; 37%
developed phosphate p1.5 mg/dl. The mean pre-transplant
FGF-23 level was 1,2187542 RU/ml. Within the first week
following transplantation, mean levels decreased to
5577579 RU/ml, which were still above normal. FGF-23 was
independently associated with serum phosphate (Po0.01),
urinary excretion of phosphate (Po0.01), and calcitriol levels
(Po0.01); PTH was not independently associated with any of
these parameters. We calculated area under the curve for
FGF-23 and PTH between the pre- and first post-transplant
levels as a summary measure of early exposure to these
phosphaturic hormones. An area under the FGF-23 curve
greater than the median was associated with a relative risk of
developing hypophosphatemia p1.5 mg/dl of 5.3 (P¼ 0.02)
compared with lower levels. Increased area under the
PTH curve was not associated with greater risk of
hypophosphatemia. Excessive FGF-23 exposure in the early
post-transplant period appears to be more strongly
associated with post-transplant hypophosphatemia than PTH.
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Hypophosphatemia owing to inappropriate urinary phos-
phate wasting is a common complication of kidney trans-
plantation, occurring in up to 93% of patients during the first
few months after transplantation.1,2 Although this phenom-
enon is usually limited to the early post-transplant period,
hypophosphatemia may persist for more than 10 years.3
Persistently increased levels of parathyroid hormone (PTH)
due to secondary hyperparathyroidism associated with
advanced chronic kidney disease (CKD) have long been
thought to be the etiology of post-transplant hypopho-
sphatemia, that is, tertiary hyperparathyroidism.2 However,
hyperparathyroidism does not appear to be the only
mechanism as inappropriate urinary phosphate wasting can
occur despite low levels of PTH, and hypophosphatemia can
persist after elevated PTH levels have normalized.4–7 Further-
more, calcitriol levels are often inappropriately low following
renal transplantation despite normal allograft function,
hypophosphatemia, and hyperparathyroidism, which should
stimulate increased calcitriol synthesis.8–10 Therefore,
mechanisms other than PTH likely contribute to the
syndrome of hypophosphatemia, urinary phosphate wasting,
and inappropriately low calcitriol levels following kidney
transplantation.
Fibroblast growth factor-23 (FGF-23) induces phosphaturia
and inhibits renal 1-a hydroxylase leading to decreased calci-
triol synthesis.11 Disorders of FGF-23 excess are characterized
by hypophosphatemia with inappropriate renal phosphate
wasting and inappropriately low calcitriol levels for the degree
of hypophosphatemia. Examples include transgenic mice
engineered to overexpress FGF-23, mice administered exo-
genous FGF-23, and humans with autosomal-dominant
hypophosphatemic rickets, fibrous dysplasia, tumor-induced
osteomalacia, and many cases of X-linked hypophosphate-
mia.11–18 Recent studies suggest that FGF-23 levels increase as
CKD progresses and contribute to the declining calcitriol
levels observed in CKD.19–21 We hypothesized that persistently
increased FGF-23 levels following kidney transplantation
contribute to the syndrome of post-transplant hypopho-
sphatemia by increasing tubular phosphate wasting and
suppressing calcitriol synthesis by inhibiting renal 1-a
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hydroxylase. We compared the strength of association between
these variables and FGF-23 relative to PTH.
RESULTS
Characteristics of the study population
The characteristics of the study population are presented in
Table 1. The immune suppression prescription was deter-
mined according to the Massachusetts General Hospital
(MGH) Transplant Unit’s departmental protocols. Most
subjects were treated with thymoglobulin induction, begin-
ning intraoperatively and for a total of three doses within
the first 3 days. All subjects except one were prescribed cor-
ticosteroids, mycophenolate mofetil, and tacrolimus for main-
tenance of immune suppression. These agents were initiated
immediately before the transplant and were dosed according
to an identical internal dosing protocol. One subject did not
receive tacrolimus or mycophenolate but instead underwent a
combined bone marrow kidney transplant as part of an
experimental immune tolerance protocol.
Phosphorus and vitamin D metabolism post-transplantation
Baseline, pre-transplant laboratory test results are presented
in Table 2. Figure 1 illustrates the scatter plots for serum
creatinine (a), potassium (b), phosphate (c), fractional
excretion of phosphate (FEPO4) (d), FGF-23 (e), PTH (f),
and calcitriol (g) plotted against the days post-transplant.
Pre-transplant levels are plotted at time¼ 0. Serum creatinine
levels normalized quickly in the majority of subjects by the
time of their first post-transplant blood sampling (Figure 1a).
There were only five episodes of hypokalemia (serum
potassium was o3.4 meq/l) during the study period (Figure
1b). In one subject this was present pre-transplant, and
another subject accounted for two of the remaining four
episodes of hypokalemia. All instances of post-transplant
hypokalemia occurred after day 27, long after the acute
reduction in serum creatinine that accompanies the osmotic
diuresis immediately following transplantation. In contrast,
85% of subjects developed post-transplant hypophosphate-
mia (Figure 1c), defined as a serum phosphate o2.6 mg/dl;
37% developed severe post-transplant hypophosphatemia,
defined as a level p1.5 mg/dl. The dissociation between
hypophosphatemia and hypokalemia suggests that post-
transplant hypophosphatemia was not caused by nonspecific
tubular dysfunction.
The mean pre-transplant FGF-23 level was 12187542 RU/
ml. Mean FGF-23 levels decreased to 5577579 RU/ml within
the first week following transplantation (Figure 1e), but these
levels remained significantly above mean levels reported in
healthy populations (55750–59742 RU/ml).16,22 After trans-
plant, no subjects developed hypercalcemia and none were
treated with sirolimus, cyclosporine, phosphorus supplements,
phosphorus binders, nutritional vitamin D supplements,
active vitamin D preparations, or cinacalcet.
The results of the regression analyses are presented in
Table 3. Both FGF-23 and PTH were associated with the
serum phosphate in univariate analyses. When both were
included together in a multivariate model, only FGF-23
remained independently associated with serum phosphate
levels. Only FGF-23 was independently associated with
FEPO4 in both univariate and multivariate analyses. Vitamin
D deficiency, defined as a 25D level o30 ng/ml, was present
in 20 of the 27 subjects at the time of transplantation but only
one subject was severely deficient (p10 ng/ml) with a level of
9.7 ng/ml. Although 25D deficiency is a known cause of
secondary hyperparathyroidism,23 there was no association
between 25D levels and PTH (r¼0.03; P¼ 0.9), and
baseline 25D levels were not associated with increased risk of
developing hypophosphatemia. FGF-23 was inversely related
Table 1 | Patient characteristics (n=27)
Age (mean7s.d.) 44.5711.8
Gender (n)
Women 12
Men 15
Race (n)
Caucasian 23
African-American 3
Hispanic 1
Etiology of kidney disease (n)
Diabetes mellitus 3
Hypertension 2
Glomerulonephritis 11
Polycystic kidney disease 4
Other 7
Transplant (n)
First 19
Second 8
Donor (n)
Living related 15
Living unrelated 12
Previous treatment (n)
Dialysis 18
Pre-emptive transplant 9
Sensitization (n)
None 9
0–50% 16
450% 2
Induction therapy (n)
None 6
Thymoglobulin 21
s.d., standard deviation.
Continuous variables are expressed as mean7s.d.
Table 2 | Results of baseline, pre-transplant laboratory tests
Creatinine (mg/dl) 6.872.3
Phosphate (mg/dl) 5.371.7
Intact parathyroid hormone (pg/ml) 305 (123, 546)
FGF-23 (RU/ml) 12187542
25(OH) vitamin D3 (ng/ml) 2378
1a,25(OH)2 vitamin D3 (pg/ml) 13.5 (8, 27)
FGF, fibroblast growth factor.
Normally distributed variables are expressed as mean7s.d., others as median (25th
and 75th percentiles).
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to calcitriol and was the only independent predictor of
calcitriol levels in univariate analyses; there was no associa-
tion between calcitriol and PTH or 25D levels (Table 3). In a
multivariate model adjusting for 25D levels, FGF-23
remained the only parameter that was independently
associated with calcitriol (inversely). To further exclude the
possibility that 25D deficiency affected the results, we
repeated the regression analyses after excluding subjects with
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Figure 1 | Scatter plots for (a) serum creatinine, (b) potassium, (c) serum phosphate, (d) FEPO4, (e) FGF-23, (f) PTH, and (g) calcitriol
plotted against the days post-transplant. Pre-transplant levels are plotted at time¼ 0. The shaded area in (b, c, and f) represents the
normal range of these variables.
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25D levelso15 ng/ml. This left 22 subjects in the analysis but
did not change the results. FGF-23 alone remained
independently associated with serum and urinary phosphate
levels and calcitriol levels during the post-transplant
period.
FGF-23 versus PTH in post-transplant hypophosphatemia
Five subjects had PTH levels o100 pg/ml before transplant.
Nonetheless, four of these subjects developed hypophos-
phatemia with phosphate levels o2.0 mg/dl; two developed
severe hypophosphatemia (p1.5 mg/dl). Interestingly, one of
these subjects had undergone a subtotal parathyroidectomy
for severe secondary hyperparathyroidism before transplant-
ation. His pre-transplant PTH was 133 pg/ml and FGF-23
was 1800 RU/ml. On post-transplant day 4, he developed
hypophosphatemia with a serum phosphate of 2 mg/dl. The
subject who never received tacrolimus also developed
hypophosphatemia with a nadir of 1.4 mg/dl.
To further evaluate the relative importance of FGF-23
versus PTH in the development of severe post-transplant
hypophosphatemia, we examined the likelihood of develop-
ing a serum phosphate level p1.5 mg/dl according to three
different measures of FGF-23 and PTH exposure: the
absolute pre-transplant levels, the immediate percent reduc-
tion in levels post-transplant, and the overall hormone
exposure during the early post-transplant period measured
by the area under the FGF-23 and PTH curves. There was a
nonsignificant trend towards increased risk of developing
severe post-transplant hypophosphatemia among subjects
whose pre-transplant FGF-23 levels were above the median
compared to those below the median (relative risk
(RR)¼ 2.5; P¼ 0.08). Subjects whose pre-transplant PTH
levels were above the median were not at increased risk
of developing severe post-transplant hypophosphatemia
compared to those with levels below the median
(RR¼ 0.43; P¼ 0.10).
Next, we examined whether severe post-transplant hypo-
phosphatemia might be linked to persistent elevations of
FGF-23 or PTH rather than the magnitude of elevation in the
baseline, pre-transplant levels (Figure 2). First, we analyzed
the risk of severe post-transplant hypophosphatemia accord-
ing to the percent change in individual subjects’ FGF-23 and
PTH from the pre- to the first post-transplant levels.
Compared to those subjects whose initial reduction in
FGF-23 levels was above the median, those whose FGF-23
levels persisted at higher levels (percent reduction in FGF-23
levels below the median) were more likely to develop
hypophosphatemia (RR¼ 3.2; P¼ 0.05). In contrast, there
was no association between the magnitude of the initial
reduction in PTH levels and subsequent risk of severe
hypophosphatemia: subjects with persistent elevation of
PTH (percent decline in PTH levels below the median) had
a RR of developing severe hypophosphatemia of 1.3 (P¼ 0.7)
compared to those with a percent decline in PTH levels
above the median.
Finally, we examined area under the FGF-23 and PTH
curves spanning the pre- and first post-transplant levels as
a summary measure of subjects’ overall initial exposure
to these hormones. The RR of developing severe hypo-
phosphatemia was 5.3 (P¼ 0.02) among those whose area under
the FGF-23 curve was greater than the median compared to
those below the median. In contrast, the RR of developing
severe hypophosphatemia was less likely (RR¼ 0.2; P¼ 0.01)
among those whose area under the PTH curve was greater
than the median compared to those below the median, the
opposite of what would be expected if post-transplant
hypophosphatemia was mediated by excessive PTH exposure.
DISCUSSION
In this prospective longitudinal study of 27 patients under-
going living donor kidney transplantation, FGF-23 rather
than PTH appeared to be the primary factor accounting
Table 3 | Results of the regression analyses modeling serum phosphate, fractional excretion of phosphate, and calcitriol levels
Univariate Multivariate
b s.e. z P-value b s.e. z P-value
Dependent variable: Serum phosphate levels
FGF-23 0.001 o0.001 3.93 o0.001 0.001 o0.001 3.84 o0.001
PTH 0.001 o0.001 1.97 0.05 0.001 o0.001 1.51 0.13
Dependent variable: Fractional excretion of phosphate
FGF-23 0.011 0.005 2.44 0.01 0.011 0.005 2.38 0.02
PTH 0.015 0.012 1.29 0.2 0.019 0.011 1.68 0.09
Dependent variable: Calcitriol levels
FGF-23 0.11 0.03 4.00 o0.001 0.11 0.03 3.84 o0.001
FGF-232 o0.001 o0.001 3.06 0.002 o0.001 o0.001 2.82 0.005
FGF-233 o0.001 o0.001 2.54 0.01 o0.001 o0.001 2.27 0.02
PTH 0.005 0.007 0.68 0.5 0.009 0.007 1.31 0.2
25D 0.04 0.26 0.15 0.9 0.20 0.23 0.86 0.4
b, beta coefficient; 25D, 25(OH)2 vitamin D; FGF, fibroblast growth factor; PTH, parathyroid hormone; s.e., standard error; z, z statistic.
All models account for individual subjects as a random effect and days post-transplant as the repeated-measures time factor. b coefficients refer to change in dependent
variable per unit increase in the independent variables: per RU/ml for FGF-23; per pg/ml for PTH; per ng/ml for 25D.
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for the syndrome of post-transplant hypophosphatemia.
Increased FGF-23 but not PTH levels were independently
associated with decreased serum phosphate levels and
increased phosphate wasting marked by increased FEPO4.
The risk of developing severe hypophosphatemia was more
tightly linked to subjects’ overall exposure to FGF-23 during
the immediate post-transplant period compared with the
corresponding values for PTH. Furthermore, hypophosphat-
emia developed in four of the five subjects with low PTH
levels before transplantation including one who had under-
gone a subtotal parathyroidectomy. In addition to these
results, a critical observation was the strong inverse associa-
tion between FGF-23 excess and persistently decreased
calcitriol levels. Although increased PTH levels could
confound the associations between FGF-23 and serum and
urinary phosphate levels, low calcitriol levels persisted
following transplantation, despite excessive PTH, a healthy
allograft, and hypophosphatemia, each of which should have
stimulated calcitriol production. This finding supports an
independent inhibitory effect of FGF-23 on renal 1-a
hydroxylase. Collectively, these results support a leading role
for FGF-23 in the development of hypophosphatemia and
decreased calcitriol levels following kidney transplantation,
and add to the growing body of evidence that implicate FGF-
23 in a variety of human disorders of phosphate metabolism.
To date, FGF-23 has been implicated in the pathogenesis
of several rare disorders of abnormal phosphate homeostasis
that are characterized by phosphate wasting, hypophos-
phatemia, and relative calcitriol deficiency and that were
initially thought to be due to elusive ‘phosphatonins.’ For
example, most patients with tumor-induced osteomalacia
have mesenchymal tumors that secrete excessive FGF-23.12
Likewise, hypophosphatemia in patients with fibrous dyspla-
sia is due to excessive secretion of FGF-23 by dysplastic bone
lesions.15 In autosomal-dominant hypophosphatemic rickets,
a mutation in the FGF-23 cleavage site renders it resistant to
inactivation leading to excessive accumulation of the
hormone.24,25 FGF-23 levels are also increased in most
patients with X-linked hypophosphatemia, although the
pathogenic link between mutations in the PHEX gene
(phosphate-regulating gene with homologies to endopepti-
dases on the X chromosome) and excess FGF-23 remains
incompletely understood.16
Based on these results in rare diseases, subsequent studies
demonstrated a role for FGF-23 in normal phosphorus
metabolism22,26 and in the pathogenesis of nephrolithiasis.27
Furthermore, FGF-23 levels increase as kidney function
declines and are independently associated with early and
progressive calcitriol deficiency21 and thus may contribute to
the pathogenesis of secondary hyperparathyroidism in CKD.
Dialysis patients, whose chronic hyperphosphatemia is
thought to stimulate constitutive FGF-23 secretion, demons-
trate the most dramatically increased FGF-23 levels.19,28
Based on the current study, we propose that post-transplant
hypophosphatemia is attributable in part to the persistence of
this excessive FGF-23 secretion into the post-transplant
period, resulting in urinary phosphate wasting by the healthy
allograft that, unlike the native kidney, is capable of
responding to the phosphaturic hormone. This phenomenon
is analogous to post-transplant hypercalcemia caused by
persistent or tertiary hyperparathyroidism. It is still unclear
why excessive FGF-23 secretion persists post-transplant, how
involution of excessive FGF-23 secretion eventually occurs
and why, in some cases, hypophosphatemia can persist for
months following transplantation.3 In adults, FGF-23 is
produced mostly by bone.29 Perhaps uremic bone develops
resistance to the inhibitory stimuli to decrease FGF-23
secretion because of the preceding months to years of
excessive FGF-23 stimulation.
FGF-23 suppresses sodium-dependent phosphate reab-
sorption by inhibiting the expression of the types IIa and
IIc sodium-dependent phosphate co-transporters in the
brush border of renal proximal tubules.30 PTH induces
phosphaturia through a similar mechanism, but studies
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Figure 2 | Pre- and first post-transplant (a) FGF-23 and (b) PTH levels in subjects who did or did not develop severe hypophosphatemia
(p1.5 mg/dl). Individual subjects’ levels are connected. (a) The RR of developing severe hypophosphatemia was 5.3 (P¼ 0.02) among those
whose area under the FGF-23 curve was greater than the median compared to those below the median. (b) The RR of developing severe
hypophosphatemia was 0.2 (P¼ 0.01) among those whose area under the PTH curve was greater than the median compared to those below
the median.
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of parathyroidectomized animals demonstrate that the
phosphaturic effect of FGF-23 is independent of PTH.31,32
Although our data support an independent effect of FGF-23
on renal phosphate handling, differentiating the effects of
FGF-23 from those of PTH in human studies is challenging,
especially when levels of both hormones are elevated as in the
post kidney transplant model. We had hoped to recruit
additional subjects who had previously undergone parathyroid-
ectomy, but only one such additional patient underwent a
transplant during the recruitment period and she declined
participation. Nevertheless, studying calcitriol levels follow-
ing kidney transplantation provides an opportunity to isolate
the effects of FGF-23 from PTH in vivo because PTH
stimulates the renal 1a-hydroxylase whereas FGF-23 is a
direct inhibitor.32,33 The observation that calcitriol levels
remain low in association with increased FGF-23 despite
normal allograft function and the stimulatory effects of
hypophosphatemia and hyperparathyroidism highlights the
central regulatory role of FGF-23. This observation is
supported by the finding that mice which are genetically
engineered to express excessive FGF-23 demonstrate persis-
tent inhibition of 1a-hydroxylase activity, despite the
development of secondary hyperparathyroidism.34 Given
the pleiotropic effects of calcitriol, including its effects on
the immune system that may beneficially impact allograft
survival,35,36 further studies are needed to explore novel
methods of interrupting those factors which inhibit renal 1a-
hydroxylase and thereby delay the recovery of normal
calcitriol levels.
A limitation of the study is that we measured FGF-23
levels using an assay that detects C-terminal fragments along
with the biologically active molecule instead of using the
intact FGF-23 assay that has recently become available.
Although C-terminal fragments may accumulate preferen-
tially as renal function declines, for the same reason, they are
likely to be eliminated more quickly following transplanta-
tion for the same reason. Importantly, the longitudinal,
repeated-measures design limited to subjects who experi-
enced prompt allograft function enabled us to observe
significant associations between FGF-23 and the outcome
variables, despite potential imprecision in the assay which
would increase variability. In addition, FGF-23 is one of the
several putative phosphatonins that could contribute to post-
transplant hypophosphatemia. Additional studies are needed
to measure the effects of other phosphatonins such as matrix
extracellular phosphoglycoprotein, frizzled related protein 4,
and FGF-7.29,37
Likewise, the PTH assay we used detects both the
‘bio-intact’ 1–84 molecule and 7–84 fragments. Although
certain reports suggest that PTH 7–84 may antagonize the
actions of PTH 1–84 on bone,38 other investigators were
unable to demonstrate a clear effect of 7–84 levels on bone
histology.39,40 There is even less data on the effects of 7–84
fragments on phosphate transport and calcitriol metabolism.
Accordingly, the therapeutic targets for PTH levels recom-
mended by international management guidelines are based
on the intact PTH assay we used,41,42 which remains the
standard assay for clinical trials of secondary hyperpara-
thyroidism in CKD.43,44 Furthermore, prior data in patients with
renal failure have demonstrated nearly complete correlation
(r¼ 0.92) between the intact PTH assay we used and the
‘bio-intact’ PTH assay that detects only PTH 1–84.43
Although the absolute concentrations of PTH would have
differed using a ‘bio-intact’ assay, the results would have been
collinear with the results we obtained and thus, would have
been unlikely to alter the associations we observed.
Confounding by the immunosuppressive drugs that
subjects received is another potential limitation. Although
high-dose steroids and tacrolimus have been linked to renal
phosphate wasting,7,45,46 hypophosphatemia is common
following kidney transplantation but does not typically occur
after other solid organ transplants where similar immuno-
suppressive regimens are used, often in higher doses.47 This
suggests that although immunosuppressive agents might
exacerbate phosphaturia following kidney transplantation,
they are unlikely to be the primary pathogenic factor. In the
current study, several factors argue against significant
confounding by the immune suppression. Nearly all patients
were on an identical immunosuppressive regimen, yet not all
patients developed hypophosphatemia. In those affected, the
severity varied despite the homogeneity of the treatment
protocol. During the course of the longitudinal follow-up,
hypophosphatemia resolved yet the immunosuppressive
agents that were administered remained. One subject who
never received tacrolimus or mycophenolate developed
hypophosphatemia. Furthermore, the significant associations
we observed between several indices of phosphorus homeo-
stasis and FGF-23 would not be expected if the phosphate
losses were nonspecifically related to extraneous factors such
as immune suppression. Finally, although immunosuppres-
sive drugs have been linked to phosphate wasting in some
studies, there are limited data to suggest that these agents
confound the strong association we observed between
increased FGF-23 and decreased calcitriol levels.
Vitamin D deficiency (25Do30 ng/ml) is common in the
general population, in patients with kidney disease, and was
also common in our study population.23,48 We do not
believe, however, that low levels of 25D significantly affected
the results. Although 25D levels of 15–30 ng/ml are associated
with modestly increased PTH levels,23 we are unaware of any
reports that indicate an increased risk of hypophosphatemia
in patients with a mild reduction in 25D levels. Furthermore,
hypophosphatemia in patients with severe vitamin D
deficiency is mediated by PTH-induced urinary phosphate
wasting in addition to decreased intestinal absorption of
dietary phosphorus. In this study, there was no correlation
between PTH and 25D levels, and we found no association
between PTH levels and phosphaturia or hypophosphatemia.
Similarly, there was no association between baseline 25D
levels and subsequent risk of developing mild or severe
hypophosphatemia. We adjusted the multivariate models for
25D levels and this did not alter the results. Similarly, the
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results did not change when the analyses were restricted to
subjects with 25D levels 415 ng/ml. Decreased 25D levels
appear to have had minimal impact on our results.
It could be argued that post-transplant hypophosphatemia
represents more of a laboratory test nuisance rather than a
clinically important complication of kidney transplantation.
The primary goals of this study, however, were to examine
the hormonal mechanisms underlying post-transplant hypo-
phosphatemia and to obtain novel insight into the in vivo
biology of FGF-23 in humans. We do not propose FGF-23 as
a diagnostic tool to predict hypophosphatemia in transplant
recipients, and we did not aim to study the incidence of
hypophosphatemia after living versus cadaveric donor
transplants. Furthermore, although post-transplant hypo-
phosphatemia is usually self-limited and asymptomatic in
most cases, there are reports of patients with protracted,
symptomatic hypophosphatemia that is difficult to treat.3
Designing appropriate treatment strategies for those patients
requires further understanding of disease mechanisms. The
current study might explain the shortcomings of our current
management strategies. High doses of phosphorus supple-
ments and active vitamin D preparations both induce
increased FGF-23 secretion and thus promote further
phosphaturia, which would seem to offset their benefit.49
Unfortunately, the current study does not suggest new
management approaches that can be immediately integrated
into clinical practice. The development of novel approaches
for the future will require further insight into the regulation
of FGF-23 and its receptor in order to learn how to facilitate
more rapid involution of its secretion or mechanisms of
blocking its effects on the kidney.
MATERIALS AND METHODS
Study population
We performed a longitudinal prospective cohort study of 27 patients
undergoing living donor kidney transplantation at MGH. The
Transplant Unit at MGH serves a diverse patient population from
Boston and surrounding areas. All patients aged 18 years or older
were eligible for the study. Subjects were excluded if they had a
hematocrit o27%, a preexisting phosphate wasting disorder, or if
they underwent cadaveric transplantation. Patients undergoing
cadaveric transplantation were excluded because of the greater risk
of delayed graft function with associated oliguria and hyper-
phosphatemia that would confound the analyses. In addition, the
uniform pre-transplant schedule in living recipients allowed written
informed consent to be obtained at the last pre-transplant visit 1
week before the procedure. The study adhered to the Declaration of
Helsinki Principles and was approved by the Human Research
Committee at MGH.
Procedures, assays, and calculations
Blood and urine samples were collected before transplantation and
longitudinally thereafter. The first post-transplant specimens were
collected at the time of the creatinine nadir, which was typically 4–5
days post-transplant. Subsequently, samples were collected every 2
weeks during the first 2 months, then at 3 and 6 months post-
transplant coinciding with routine follow-up visits to the Transplant
Clinic. To minimize confounding, sample collection on individual
patients was discontinued if they developed allograft dysfunction.
Three subjects developed acute rejection necessitating discontinua-
tion of blood sampling. Blood sampling was discontinued pre-
maturely in another subject who developed significant anemia.
Six subjects from remote New England areas resumed their care with
their referring nephrologists near their homes after completing 3
months of care at the transplant center. Thereafter, these six subjects
were unavailable to continue their sample collections for the study.
A total of 119 observations were collected in the 27 subjects; the
mean number of follow-up visits was 4. 4 per subject and the follow-
up ranged from 4 to 153 days post-transplant.
After collection, samples were stored for less than 2 h at 51C.
Upon arrival to the laboratory, the plasma and serum samples were
centrifuged at 3200 r.p.m. in a Beckman Coulter Spintrol DLX
centrifuge for 9 min, aliquoted, and stored at 801C for future
analysis. Urine samples were shaken, aliquoted, and also stored at
801C. When enrollment was complete, the stored samples
underwent a single thaw followed by batched assay of individual
biomarkers in the Core Laboratory of the Mallinckrodt General
Clinical Research Center at MGH.
FGF-23 was measured using a two-site enzyme-linked immuno-
sorbent assay that uses affinity purified anti-FGF-23 antibodies
directed against two epitopes within the carboxy-terminal portion of
FGF-23 (Immutopics, San Clemente, CA, USA); this assay measures
intact FGF-23 as well as C-terminal fragments.16 The inter- and
intra-assay coefficients of variation were 7.3 and 5.0%, respectively.
The assay has been used in previous studies of CKD patients.19,21
PTH was measured using a two-site, second-generation enzyme-
linked immunosorbent assay that detects intact PTH (Immutopics,
San Clemente, CA, USA), with inter- and intra-assay coefficients of
variation of 7.7 and 3.2%, respectively.39 Calcitriol was measured
using a radioimmunoassay (DiaSorin Inc., Stillwater, MN, USA)
with coefficients of variation o6.5% at concentrations o32.5 pg/l.
In order to adjust for differences in vitamin D stores, we also
measured baseline serum 25(OH)2 vitamin D3 (25D) levels using a
radioimmunoassay (DiaSorin Inc., Stillwater, MN, USA). The
coefficient of variation for the 25D assay was o2.3% at a range of
o30 ng/ml. Serum creatinine, calcium, phosphate and urine
creatinine, and phosphate were measured using routine assays.
The FEPO4 was the primary measure of renal phosphate handling.
50
FEPO4 is calculated by dividing the ratio of urine to serum
phosphate by the ratio of urine to serum creatinine. This calculation
standardizes urinary phosphate excretion for differences in urine
concentration and the simultaneous serum phosphate. We used
FEPO4 instead of the renal threshold of phosphate reabsorption
standardized to glomerular filtration rate (TmPi/glomerular filtra-
tion rate), as the latter has been validated for use only in fasting
subjects50 and our subjects were not asked to fast before sample
acquisition. Osmotic diuresis after transplantation is a potential
cause of hypophosphatemia that is independent of FGF-23 and
PTH. Hypokalemia is a common consequence of osmotic diuresis.
To assess whether hypophosphatemia represented nonspecific
tubular wasting, we also examined potassium levels during the
post-transplant period.
Statistical analysis
Patient characteristics are reported using standard descriptive
statistics. Crude levels of analytes expressed as a function of time
post-transplantation are presented in scatter plots. Pre-transplant
values were considered to be collected at time¼ 0. Mixed model
linear regression analyses that account for the repeated-measures
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design were used to test our hypotheses that FGF-23 was more
strongly associated with serum phosphate, FEPO4, and calcitriol
levels compared with PTH. In the models, time was treated as a
linear covariate represented as the number of days post-transplant
(random slopes models). Mixed-model regression analyses are
robust to different numbers of follow-up observations within
individual subjects.51 Analyses that modeled calcitriol levels as the
dependent variable were also adjusted for 25D levels. When
necessary, squared and cubic terms were included in the regression
models to account for exponential relationships between predictors
and dependent variables.
To further assess the relative contributions of FGF-23 versus PTH
in the development of post-transplant hypophosphatemia, we
examined the risk of developing hypophosphatemia according to
the pre-transplant FGF-23 and PTH levels, and according to the
percent change from the pre- to the first post-transplant levels. We
also examined the risk of developing hypophosphatemia according
to the area under the FGF-23 and PTH curves spanning the early
post-transplant period as a summary measure of overall initial
exposure to these phosphaturic hormones. Analyses were performed
using Stata Intercooled 7.0 (Stata Corporation, College Station, TX,
USA). Two-sided P-values p0.05 were considered statistically
significant.
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